Axcella Health is a clinical-stage biotechnology company pioneering the use of endogenous metabolic modulators (EMMs) to treat complex diseases. The company focuses on developing therapeutic candidates that combine multiple amino acids and their derivatives in specific ratios to impact various biological pathways simultaneously. Axcella's lead candidates target non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. The company operates in the biotechnology sector, primarily serving patients with complex metabolic and liver diseases. Axcella's business model involves advancing its product candidates through clinical trials and regulatory approval processes, aiming to bring innovative treatments to market. Revenue generation is anticipated through the commercialization of these therapeutic candidates, either independently or through partnerships with larger pharmaceutical companies. The company emphasizes a culture of ownership, collaboration, and urgency in advancing its pipeline.

Keywords: EMMs, NASH, OHE, biotechnology, clinical-stage, metabolic diseases, liver diseases, amino acids, therapeutic candidates, multi-targeted.